| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Our goal is to develop novel therapeutic methods for severe inflammatory diseases such as atopic dermatitis (AD) and arteriosclerosis targeting PKCeta. We assessed the effects of siRNA and pseudosubstrate peptide for PKCeta on AD-like dermatitis in Nc/Nga mice, model for AD. Administration of PKCeta siRNA using some transdermal delivery systems suppressed deterioration of dermatitis including itching or fissure on the back skin and ear. Moreover, novel siRNA sequences for PKCeta inhibiting its expression significantly were identified. Furthermore, we examined the effects of PKCeta gene knockout in arteriosclerosis model mice; ApoE by ApoE/PKCeta double knockout mice.
|
